Evidence map›Paper›PMID 39086540›Full record

ArticleFrontiers in nutrition2024

Enhanced oral bioavailability of cannabidiol by flexible zein nanoparticles:

YingLan Nie, Yan Kong, Juan Peng, Jian Sun, Bin Fan

Abstract read
In one paragraph

Article in Frontiers in nutrition, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Development andDrug delivery · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

YingLan Nie *Beijing Key Laboratory of Basic Research on Traditional Chinese Medicine to Prevent and Control Major Diseases, Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing, China.
Yan Kong *Beijing Key Laboratory of Basic Research on Traditional Chinese Medicine to Prevent and Control Major Diseases, Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing, China.
Juan PengBeijing Key Laboratory of Basic Research on Traditional Chinese Medicine to Prevent and Control Major Diseases, Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing, China.
Jian SunBeijing Key Laboratory of Basic Research on Traditional Chinese Medicine to Prevent and Control Major Diseases, Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing, China.
Bin FanBeijing Key Laboratory of Basic Research on Traditional Chinese Medicine to Prevent and Control Major Diseases, Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Cannabidiol (CBD) has a variety of pharmacological effects including antiepileptic, antispasmodic, anxiolytic and anti-inflammatory among other pharmacological effects. However, since CBD is a terpene-phenolic compound, its clinical application is limited by its poor water solubility, low stability, and low bioavailability. Methods: In this study, we used several strategies to address the above problems. Hydrochloric acid was used to modify zein to improve the molecular flexibility. Flexible zein nanoparticles (FZP-CBD) loaded with CBD was prepared to improve the stability and bioavailability of CBD. The parameters were evaluated in terms of morphology, particle size (PS), polydispersity index (PDI), zeta potential (ZP), entrapment efficiency (EE%), loading capacity (LC%), and storage stability. Simulated gastrointestinal fluid release experiment and bioavailability assay were applied in the evaluation. Results: The simulated gastrointestinal fluid experiment showed that the release rates of FZP-CBD and natural zein nanoparticles (NZP-CBD) loaded with CBD were 3.57% and 89.88%, respectively, after digestion with gastric fluid for 2 h, 92.12% and 92.56%, respectively, after intestinal fluid digestion for 2 h. Compared with NZP-CBD, the Discussion: The experimental results showed that FZP-CBD could protect most of the CBD from being released in the stomach, and then control its release in the intestines, promote the absorption of CBD in the small intestine, and increase the bioavailability of CBD. Therefore, FZP-CBD could improve the utilization value of CBD and provide a new idea for the application of CBD in medicine and pharmacy.

Indexed as

bioavailabilitycannabidiolcannabidiol releaseflexible zeinnanoparticle

Identifiers

PMID39086540
PMCPMC11289775

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.